BT3.F Lineage Cell Therapeutics Inc

Healthcare Metals & Mining Frankfurt Exchange
0.9720 EUR
Close of Nov 12, 2026
0.7820 1.68
Market cap
EUR 246M
P/E
-
P/B
4.37x
ROE
-10.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BT3.F undervalued?

Graham number

The Graham number of Lineage Cell Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lineage Cell Therapeutics Inc fundamental analysis

No fundamental analysis for Lineage Cell Therapeutics Inc yet.

Lineage Cell Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter …

Full company profile